Mofezolac

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Mofezolac（以前称为 Disopain 或 N-22）是一种高选择性 COX-1（环氧合酶-1）抑制剂，COX 选择性指数 > 6000。

Mofezolac (formerly known as Disopain or N-22) is a highly selective COX-1 (cyclooxygenase-1) inhibitor with COXs selectivity index > 6000.(In Vitro):Mofezolac inhibits platelet aggregation with an IC50 of 0.45 μM in human platelet rich plasma (hPRP) assay.Mofezolac slightly increase Bortezomib cytotoxic effect on multiple myeloma (MM) cell lines (NCI-H929 and RPMI-8226) and affects MM cell cycle and apoptosis when co-administered with the proteasome inhibitor Bortezomib.(In Vivo):Mofezolac (1-30 mg/kg; oral administration; once) treatment results in the suppression of writhing induced by the intraperitoneal injection of phenyl-p-benzoquinone in mice.

Mofezolac inhibits platelet aggregation with an IC50 of 0.45 μM in human platelet rich plasma (hPRP) assay. Mofezolac slightly increase Bortezomib cytotoxic effect on multiple myeloma (MM) cell lines (NCI-H929 and RPMI-8226) and affects MM cell cycle and apoptosis when co-administered with the proteasome inhibitor Bortezomib.

Mofezolac (1-30 mg/kg; oral administration; once) treatment results in the suppression of writhing induced by the intraperitoneal injection of phenyl-p-benzoquinone in mice. Animal Model:Female ddY mice (4 week old, 18-27 g) injected with phenyl-p-benzoquinone (PQ) Dosage:1 mg/kg, 3 mg/kg, 10 mg/kg, 30 mg/kg Administration:Oral administration; once Result:Dose-dependently suppressed the writhing induced by PQ injection in mice.

——

Chromatin/Epigenetic

COX

COX

Inflammation/Immunology

Musculoskeletal disorders; Pain; Postoperative pain; Rheumatic disorders

78967-07-4

339.35

C19H17NO5

>98% (HPLC)

DMSO:10 mM;Water:Insoluble;Ethanol:Insoluble

COc1ccc(cc1)-c1noc(CC(O)=O)c1-c1ccc(OC)cc1

2-(34-bis(4-methoxyphenyl)isoxazol-5-yl)acetic acid

(-20℃)

With Ice Pack

≥ 2 years